Business Wire

Verlingue Boosts Employee Benefits Division and Extends UK Footprint With Brunsdon Employee Benefits Acquisition

Share

Verlingue has announced the acquisition of Gloucester-based Brunsdon Employee Benefits, an independently owned Employee Benefits specialist. The deal supports Verlingue’s recent expansion in the Midlands and Southwest and significantly boosts its employee benefits capabilities in the SME and mid-corporate market.

It also aligns with Verlingue’s 2024 strategic plan to create a major European, family-owned, independent insurance broker and has reinforced its ambition after the acquisition, early July, of INSER, one of the leading independent players in the Italian insurance brokerage market.

Brunsdon Employee Benefits provides schemes and advice to a broad portfolio of clients in the Southwest and across the UK.

The whole of the Brunsdon Employee Benefits team will join Verlingue as part of the deal and current Managing Director, Sebastian Merritt, will take on the role of Head of Employee Benefits reporting into CEO Mike Latham.

Mark Pugh, currently Head of Employee Benefits, will take the opportunity to relinquish previous operational responsibilities and will now concentrate on expanding and delivering Verlingue’s Multinational, Major Client and Partnership propositions.

The acquisition follows hot on the heels of the launch of a new general insurance office in Birmingham covering the Midlands and South West.

Mike Latham, CEO, Verlingue UK, commented:
“This is an exciting acquisition for Verlingue which not only expands our footprint in the employee benefits market but builds on our recent expansion as a group in the Midlands and South West. Our strategy is to continue to grow our employee benefits operation and we are actively looking for additional acquisitions this year and beyond!”

Benjamin Verlingue, director of International Subsidiaries, Verlingue, added:
“The acquisition of Brunsdon Employee Benefits will help us to reinforce our presence in the UK and to become a major player in this strategic market for insurance. Our aspiration remains to preserve our status as an independent, family-run broker, while pursuing sustained development through highly competent teams deployed across Europe to bring to our customers all the services they need at international level”.

About Verlingue

An insurance broker specialising in business protection, Verlingue is a subsidiary of the Adelaïde Group.

Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its customers’ value creation and performance.

With offices in France, Portugal, Switzerland, Great Britain and Italy, and through partners in over 100 countries, Verlingue works with its customers over the long term and at all times to better understand and plan ahead for new risks in order to develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).

1,350 employees, 550 of whom are based outside France
€2,350m in premiums negotiated on behalf of its customers
Operating out of 5 countries in Europe
LinkedIn / www.verlingue.fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Adelaïde Group – Thomas Barbelet – thomas.barbelet@verlingue.fr – +33(0)6 72 75 49 14
Epoka Agency – Lucie Fortin – lfortin@epoka.fr – +33(0)6 19 68 70 18

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye